butorphanol

Trade name: stadol

Small moleculeapproved

Approved

Aug 22, 1978

Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord. Butorphanol has agonistic activity at the κ-receptor and antagonistic activity at the μ-receptor. It also exhibits partial agonistic activity at the σ-receptor. — NCATS

Clinical trial activity

17 trials · 16 clinical orgs · 10 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
8

Earliest trial started Jan 1, 2007 (NCT00510666)

Timeline

1970s

  1. Aug 22, 1978

    Bristol-Myers — Earliest FDA Approval

  2. Aug 22, 1978

    Apothecon — NDA Secondary Org

  3. Aug 22, 1978

    Bristol-Myers — NDA Organization

1990s

  1. Dec 12, 1991

    Bristol-Myers Squibb — NDA Secondary Org

  2. Jan 22, 1997

    Hospira — Marketing Organization

  3. Aug 12, 1998

    West-Ward Pharmaceutical — Marketing Organization

2000s

  1. Aug 8, 2001

    Rising Pharmaceuticals — Marketing Organization

  2. Aug 8, 2001

    Mylan — Marketing Organization

  3. Oct 23, 2001

    Baxalta — Marketing Organization

  4. Dec 4, 2002

    Apotex — Marketing Organization

  5. Apr 29, 2009

    Hikma — Marketing Organization

2010s

  1. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedPriority reviewAug 22, 1978

Chemistry & pharmacology

Loading structure…

SMILES

Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
Mol. weight
327.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral, Topical
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

Yes

Black box warning

Sources

Also known as

  • (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
  • (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
  • bc 2627
  • bc-2627
  • butorfanol
  • butorfanol
  • butorphanol
  • butorphanol
  • butorphanol
  • butorphanol
  • butorphanol
  • butorphanol
  • butorphanol
  • butorphanol
  • butorphanol
  • butorphanol
  • (-)-butorphanol
  • (-)-butorphanol
  • (-)-butorphanol
  • butorphanol tartrate
  • butorphanol tartrate
  • butorphanol tartrate
  • butorphanol tartrate
  • butorphanol tartrate
  • butorphanolum
  • butorphanolum
  • levo-bc-2627
  • levo-bc-2627
  • levo-bc-2627 tartrate
  • levo-bc-2627 tartrate
  • (-)-n-cyclobutylmethyl-3,14-dihydroxymorphinan
  • (-)-n-cyclobutylmethyl-3,14-dihydroxymorphinan
  • stadol
  • stadol
  • stadol
  • stadol ns
  • stadol ns
  • torbugesic
  • torbugesic
  • torbutrol
  • torbutrol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06031129N/AMar 1, 2023Eastern Hepatobiliary Surgery Hospital, Jinlin University
NCT06398834Phase 4Mar 1, 2022Anhui Medical University, Huazhong University of Science and Technology, Second People's Hospital of Hefei City
NCT05024799Phase 4Jan 31, 2022Qingdao University
NCT05201560N/AJan 31, 2022Fudan University
NCT06524596N/AJan 1, 2022Wuhan Children's Hospital
NCT04477733N/AAug 14, 2020Capital Medical University
NCT04490980N/AAug 1, 2020Huazhong University of Science and Technology
NCT04436224Phase 4Jul 31, 2020Southern Medical University
NCT04295109N/AMar 2, 2020Nanjing Medical University
NCT04315935Phase 4Dec 15, 2019Hebei Medical University, Hengrui Therapeutics, Inc.
NCT03429179Phase 4Dec 1, 2017Shengjing Hospital
NCT03810391Phase 2Dec 1, 2017Shengjing Hospital
NCT03398759N/AOct 1, 2017Jiao Tong University
NCT02043366N/AFeb 1, 2014Nanjing Medical University, Tianjin Medical University
NCT00795314Phase 4Nov 1, 2008Nanjing Medical University
NCT00738192Phase 4Jul 1, 2008Nanjing Medical University
NCT00510666Phase 4Jan 1, 2007Nanjing Medical University
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Nanjing Medical UniversityAcademic/Hospital5522007
Huazhong University of Science and TechnologyAcademic/Hospital2122020
Shengjing HospitalAcademic/Hospital2222017
Anhui Medical UniversityAcademic/Hospital1012022
Capital Medical UniversityAcademic/Hospital1112020
Eastern Hepatobiliary Surgery HospitalAcademic/Hospital1012023
Fudan UniversityAcademic/Hospital1112022
Hebei Medical UniversityAcademic/Hospital1012019
Hengrui Therapeutics, Inc.For profit1112019
Jiao Tong UniversityAcademic/Hospital1112017
Jinlin UniversityAcademic/Hospital1112023
Qingdao UniversityAcademic/Hospital1112022
Second People's Hospital of Hefei CityAcademic/Hospital1112022
Southern Medical UniversityAcademic/Hospital1112020
Tianjin Medical UniversityAcademic/Hospital1012014
Wuhan Children's HospitalAcademic/Hospital1112022
16 organizations
Page 1 / 1

Marketing (14)

OrganizationOrg typeRelationshipDate
ApotexFor profitMKTGDec 4, 2002
ApotexFor profitSYNDec 4, 2002
ApotheconFor profitNDA2Aug 22, 1978
BaxaltaFor profitMKTGOct 23, 2001
Bristol-MyersFor profitNDAAug 22, 1978
Bristol-Myers SquibbFor profitNDA2Dec 12, 1991
HikmaFor profitMKTGApr 29, 2009
HikmaFor profitSYNMar 12, 2002
HikmaFor profitSYNMar 12, 2002
HospiraFor profitMKTGJan 22, 1997
MylanFor profitMKTGAug 8, 2001
Rising PharmaceuticalsFor profitMKTGAug 8, 2001
Rising PharmaceuticalsFor profitSYNAug 8, 2001
West-Ward PharmaceuticalFor profitMKTGAug 12, 1998